Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics (NASDAQ: TNGX) has announced participation in two virtual investor conferences in February 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) has announced participation in two virtual investor conferences in February 2022. The Guggenheim 2022 Oncology Conference is scheduled for February 9 at 9:00 AM ET, followed by the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:00 PM ET. Live webcasts of these events will be available on the company's website, with replays accessible for 30 days post-event. Tango specializes in precision cancer medicines, employing innovative approaches to target cancer effectively.
Details
News Market Reaction – TNGX
The recorded move for TNGX in the trading session of this news was +2.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in the following upcoming virtual investor conferences in February:
Guggenheim 2022 Oncology Conference
Date: Wednesday, February 9 2022
Time: 9:00 AM ET
11th Annual SVB Leerink Global Healthcare Conference
Date: Wednesday, February 16 2022
Time: 1:00 PM ET
A live webcast of the fireside chats will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcasts will be archived on the Company's website for 30 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Investor Contact:
Sam Martin/Michael Barron
Argot Partners
tango@argotpartners.com
Media Contact:
Joshua R. Mansbach
Argot Partners
tango@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.